Galera Therapeutics Inc News - GRTX | ADVFN

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Galera Therapeutics Inc (GRTX)
Galera Therapeutics Inc (GRTX) News

Galera Therapeutics Inc (GRTX)

0.1861

-0.0214

(-10.31%)

Closed April 27 4:00PM

Delayed by 15 minutes

0.1879

0.0018

(0.97%)

After Hours: 7:55PM

Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 3 - Initial statement of beneficial ownership of securities

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial

Adriano Marchese Shares in Galera Therapeutics were halted from premarket trading on Tuesday after the Food and Drug Administration said the...

Form 8-K - Current report

Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass...

Form 8-K - Current report

Form 8-K - Current report

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage...

Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

1
Next

glenn1919

glenn1919 1 week ago

GRTX..........................................https://stockcharts.com/h-sc/ui?s=GRTX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 3 weeks ago

GRTX..........................................https://stockcharts.com/h-sc/ui?s=GRTX&p=W&b=5&g=0&id=p86431144783

FROZENFLAME

FROZENFLAME 3 weeks ago

Creeping up, let’s do it again .

FROZENFLAME

FROZENFLAME 3 weeks ago

FROZENFLAME

FROZENFLAME 4 weeks ago

Over 11 million in volume with a high of .245 $

FROZENFLAME

FROZENFLAME 4 weeks ago

Sounds good
As of December 31, 2023, Galera had cash and cash equivalents of $18.3 million. Galera expects that its existing cash and cash equivalents will enable Galera to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.

FROZENFLAME

FROZENFLAME 1 month ago

And some news will be great !

FROZENFLAME

FROZENFLAME 1 month ago

Need some volume !

FROZENFLAME

FROZENFLAME 1 month ago

Nice size bid !

FROZENFLAME

FROZENFLAME 1 month ago

Interesting price, I’m in
$GTRX

Nealio

Nealio 3 months ago

$GRTX - wants to move even higher...funds buying in? Anyone monitoring that? I need to find those links for Institutional reporting

glenn1919

glenn1919 3 months ago

GRTX............................https://stockcharts.com/h-sc/ui?s=GRTX&p=W&b=5&g=0&id=p86431144783

crowin

crowin 4 months ago

Nealio

Nealio 4 months ago

Looks like a lot of people gave up and sold too low...it may punch UP further tomorrow...certainly held gains ah's. News pending?

urge2surge

urge2surge 4 months ago

13G 12% stake. Looks ready. Mc only 7 mill, cash and tangibles 28 mill. No cash needed until 2025. Buyout candidate IMO.

0210

0210 5 months ago

Close Watch: GRTX 8 x 34 + other daily technicals curling up. Now @0.14 - 0.15 > 0.1610 - 0.171(Parabolic SAR) >> 0.32, and then up to 0.50, +233% short-term target price.

0210

0210 5 months ago

GRTX @0.14 - 0.15 fwiw. "...risk/reward is still favorable. 28 mil cash on hand, and laying off over 70% of the workforce and stopping the 2 trials, should be ample enough money to carry them through all of 2024. Already have made it clear that they don't want to go through another trial for Avasopasem, as it is costly and time consuming, so if you are buying or going long here, you are simply playing[translation: ACCUMULATING, lol ] for one of the possible strategic maneuvers..."
Source: Click here.

0210

0210 5 months ago

TP: 0.25 min 0.50 max and/or 0.42 ave.(short-term TP = 3x or +200% from 0.14-.0.15 current pps) .

Source: 3 stock analysts. Click here.

glenn1919

glenn1919 6 months ago

GRTX...................https://stockcharts.com/h-sc/ui?s=GRTX&p=W&b=5&g=0&id=p86431144783

knrorrel

knrorrel 6 months ago

Why ? do you think it will go higher soon ?

Triple nickle

Triple nickle 6 months ago

Never see these prices again

koolmc

koolmc 6 months ago

lol you were telling peeps to dump few days ago

Tom turtles

Tom turtles 6 months ago

Dumped at .145..TY stock God's...In .0919

chumfm

chumfm 6 months ago

Seen this many times.This goose is cooked.Expect chapter 11 in the near future.Good luck and good trading.

Tom turtles

Tom turtles 6 months ago

You may as well unload now...geez.. what a fiasco

Here Today

Here Today 6 months ago

And in the case of IPIX like it is here with Galera, the FDA constantly wants more testing and more testing. But yet for an experimental MRNA shot which scientists and the medical community will not truly know the effects for another 5 years on one’s health, they green light. In my opinion, it’s all about who greases whose palms!!!

Here Today

Here Today 6 months ago

Overreaction??? This looks to be going down the route of IPIX. Both of these companies Galera and Innovation Pharma had a product for OM and both of them have been rejected by the FDA. It’s amazing to me the stupidity of how it goes especially since they have nothing that really works right now and patients that develop OM usually have to stop cancer treatments and then decide whether or not to continue once the symptoms subside and heal. And the cost for a severe OM patient to be treated is very, very expensive.

wickerman

wickerman 6 months ago

$GRTX where's the guy who was pumping this trash all over iHub?
Next stop is BK and delisting.

ATM123

ATM123 6 months ago

Do the company has any IP property for buyout/merger with all the trails cancellations...

hondaboost

hondaboost 6 months ago

Over reaction: GRTX, cash: $28.4 M. "Galera estimates that its balance of cash, cash equivalents and short-term investments as of September 30, 2023 was $28.4 million. or $0.7/share . "

Here Today

Here Today 6 months ago

Not bad??? Check out market reaction. Down 50% pre market.

sc00pnDump

sc00pnDump 6 months ago

News out, need to do another phase 3 tests and submit holding back other drug to save money… not bad

mistercellphoneman

mistercellphoneman 6 months ago

website is back up

OmegaMoney29

OmegaMoney29 6 months ago

ATM123

ATM123 6 months ago

Website is down...Whats going on

Golden Cross

Golden Cross 6 months ago

Should be hearing something this week

OmegaMoney29

OmegaMoney29 6 months ago

Golden Cross

Golden Cross 6 months ago

It is possible to fill that $2 gap Omega... Depends on how good the news is...

work-n-hard

work-n-hard 6 months ago

...with Good Weather. lol

powerbattles

powerbattles 6 months ago

Fully loaded at an average.185

OmegaMoney29

OmegaMoney29 6 months ago

Early Christmas 🎄

work-n-hard

work-n-hard 6 months ago

Gap fill would be excellent.

OmegaMoney29

OmegaMoney29 6 months ago

fda news run to $2 tomorrow??

work-n-hard

work-n-hard 6 months ago

Yep, I think that it's leaking out that news is coming. Maybe this afternoon or tomorrow???

Golden Cross

Golden Cross 6 months ago

Think we have seen the bottom...Looking better here

work-n-hard

work-n-hard 6 months ago

https://www.nasdaq.com/press-release/galera-schedules-type-a-meeting-with-fda-to-discuss-next-steps-for-avasopasem-2023-09

bluebird50

bluebird50 6 months ago

What’s the intended date?

powerbattles

powerbattles 6 months ago

$GRTX According to the FDA guidance document titled “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry”, after a Type A meeting, the FDA will provide written feedback to the sponsor or applicant within 14 calendar days of the meeting. This feedback will include a summary of the meeting, any agreements reached during the meeting, and any action items that need to be addressed by either party.

Agreements that could be reached during a Type A meeting include:

Agreement on clinical trial design: The FDA may agree to a sponsor’s or applicant’s proposed clinical trial design.

Agreement on endpoints: The FDA may agree to a sponsor’s or applicant’s proposed endpoints for a clinical trial.

Agreement on statistical analysis: The FDA may agree to a sponsor’s or applicant’s proposed statistical analysis plan for a clinical trial.

Agreement on labeling: The FDA may agree to a sponsor’s or applicant’s proposed labeling for a drug product.

work-n-hard

work-n-hard 6 months ago

? I sent it the day before.

Triple nickle

Triple nickle 6 months ago

Give it 10 minutes

Galera Therapeutics

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions